Clinical Trial Update: Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome [Phase 2]

View source ↗

Summary

Phase 2 study of NGX267 oral capsules for xerostomia associated with Sjögren's syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome
• Xerostomia

Drugs mentioned

• NGX267

Snippet

Sponsor: TorreyPines Therapeutics | Conditions: Xerostomia, Sjogren's Syndrome | Phase 2 | Status: COMPLETED